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Abstract
Rab31 is a member of the Ras superfamily of small GTPases that has been linked to poor outcomes in patients with breast
cancer. The MUC1-C oncoprotein is aberrantly overexpressed in most human breast cancers and also confers a poor
prognosis. The present results demonstrate that MUC1-C induces Rab31 expression in estrogen receptor positive (ER+)
breast cancer cells. We show that MUC1-C forms a complex with estrogen receptor a (ERa) on the Rab31 promoter and
activates Rab31 gene transcription in an estrogen-dependent manner. In turn, Rab31 contributes to the upregulation of
MUC1-C abundance in breast cancer cells by attenuating degradation of MUC1-C in lysosomes. Expression of an inactive
Rab31(S20N) mutant in nonmalignant breast epithelial cells confirmed that Rab31 regulates MUC1-C expression. The
functional significance of the MUC1-C/Rab31 interaction is supported by the demonstration that Rab31 confers the
formation of mammospheres by a MUC1-C-dependent mechanism. Analysis of microarray databases further showed that (i)
Rab31 is expressed at higher levels in breast cancers as compared to that in normal breast tissues, (ii) MUC1+ and ER+ breast
cancers have increased levels of Rab31 expression, and (iii) patients with Rab31-positive breast tumors have a significantly
decreased ten-year overall survival as compared to those with Rab31-negative tumors. These findings indicate that MUC1-C
and Rab31 function in an autoinductive loop that contributes to overexpression of MUC1-C in breast cancer cells.
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Introduction
Rab proteins are members of the Ras superfamily of small
GTPases [1]. The Rab GTPases function in receptor internaliza-
tion, recycling and signaling [2]. Rab31, a Rab5 subfamily
GTPase, is involved in the trafficking of early endosomes [3].
Rab31 blocks insulin-stimulated translocation of the Glut4 glucose
transporter from endosomes to the cell membrane [4]. In addition,
Rab31 is required for transport of mannose 6-phosphate receptors
from the trans-Golgi network to endosomes [5]. Interestingly, high
levels of Rab31 expression in tumors from 280 node-negative
breast cancer patients were shown to be significantly associated
with decreased metastasis-free and overall survival [6]. However,
no insights are available regarding a potential functional role for
Rab31 in breast cancer.
Mucin 1 (MUC1) is a heterodimeric transmembrane glycopro-
tein that is overexpressed in about 90% of human breast cancers
[7,8,9]. MUC1 consists of two subunits that form a complex at the
cell membrane after translation and autocleavage of a single
polypeptide [7,9]. The MUC1 N-terminal subunit (MUC1-N)
contains glycosylated tandem repeats that are a characteristic of
mucin family members. The MUC1 C-terminal subunit (MUC1-
C) spans the cell membrane and contains a cytoplasmic domain
that interacts with diverse effectors, such as the epidermal growth
factor receptor (EGFR) and ErbB2, that have been linked to
transformation [7,9]. Overexpression of MUC1-C, as found in
human breast cancers, is sufficient to induce anchorage-indepen-
dent growth and tumorigenicity [10,11]. The overexpression of
MUC1 in transgenic mouse models is also associated with the
induction of breast tumors [12,13]. MUC1-C is internalized from
the cell membrane by clathrin-mediated endocytosis [14] and is
then recycled from endosomes back to the cell membrane [15].
The overexpression of MUC1 in breast cancer cells is also
associated with accumulation of MUC1-C in the cytoplasm by a
mechanism that likely involves retrograde trafficking during
endocytosis and movement to the endoplasmic reticulum [7,9].
Cytosolic MUC1-C interacts with importin-b and is transported to
the nucleus [16], where it interacts with estrogen receptor a (ERa)
and promotes ERa-mediated gene transcription [17].
The present studies demonstrate that MUC1-C induces Rab31
expression in breast cancer cells. MUC1-C forms a complex with
ERa on the Rab31 promoter and activates Rab31 gene transcrip-
tion. In turn, Rab31 contributes to the upregulation of MUC1-C
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e39432levels in an autoinductive loop. These findings are further
supported by the demonstration that Rab31 expression is
increased in primary breast cancers that are positive for both
ERa and MUC1.
Results
MUC1 Upregulates Rab31 Expression
Gene microarray analysis of MCF-7 breast cancer cells
demonstrated that silencing of MUC1 is associated with decreases
in Rab31 expression. To confirm this observation, MCF-7 cells
stably expressing an empty vector (MCF7/vector) or MUC1-
siRNA (MCF-7/MUC1siRNA) were analyzed for Rab31 mRNA
levels by RT-PCR. Downregulation of MUC1-C mRNA levels
was associated with a decrease in Rab31 transcripts (Fig. 1A, left).
Quantitative RT-PCR confirmed that Rab31 transcripts are
significantly lower in MCF-7/MUC1siRNA cells as compared to
that in MCF-7/vector cells (Fig. 1A, right). Similar results were
obtained when mRNA from ZR-75-1 breast cancer cells was
analyzed by RT-PCR (Fig. 1B, left) and qRT-PCR (Fig. 1B, right).
In concert with these results, MUC1-C silencing was associated
with decreases in the abundance of Rab31 protein in MCF-7
(Fig. 1C) and ZR-75-1 (Fig. 1D) cells. These findings indicate that
MUC1-C functions in upregulating Rab31 expression.
Rab31 Promoter is Activated by a MUC1-dependent
Mechanism
To assess the effects of MUC1 on Rab31 gene transcription, we
cloned a 1874 bp region upstream to the Rab31 transcription start
site and inserted those sequences in a luciferase expression vector
(pRab31-Luc). Analysis of the Rab31 promoter region incorporat-
ed into pRab31-Luc identified putative consensus binding sites for
diverse transcription factors, including multiple potential ERa
responsive elements (EREs) (Fig. 2A). Transfection of MCF-7/
vector and MCF-7/MUC1siRNA cells with pRab31-Luc demon-
strated that silencing MUC1 results in repression of the Rab31
promoter (Fig. 2B). Similar results were obtained in studies of ZR-
75-1 cells, indicating that MUC1-C confers activation of Rab31
transcription (Fig. 2C). Previous work showed that MUC1-C
associates with ERa and promotes activation of ERa target genes
[17]. To assess dependence on ERa, we transfected MCF-7 cells
with control or ERa siRNA pools to transiently decrease ERa
levels (Fig. 2D, left). Silencing of ERa was associated with a
decrease in pRab31-Luc activation, consistent with ERa-mediated
induction of the Rab31 promoter (Fig. 2D, right). To provide
further support for Rab31 gene activation by estrogen signaling,
ZR-75-1 cells were transfected with pRab31-Luc, cultured in
estrogen-depleted medium, and then stimulated with estradiol
(E2). Compared to unstimulated cells, E2 treatment was associated
with a 3-fold increase in pRab31-Luc activation (Fig. 2E). These
findings indicate that Rab31 promoter is activated by a mechanism
dependent on ERa and MUC1-C.
E2 Induces Rab31 Expression by a MUC1-C-dependent
Mechanism
In further support for involvement of ERa in Rab31 expression,
E2 treatment of MCF-7 cells was associated with a .3-fold
increase in Rab31 mRNA levels at 6 h and then a modest decline
by 24 h (Fig. 3A, left). Stimulation of ZR-75-1 cells with E2 was
also associated with a transient increase in Rab31 mRNA levels at
6 h (Fig. 3A, right). To assess dependence on MUC1-C, E2
treatment studies were performed on MCF-7/vector and MCF-7/
MUC1siRNA cells. Stimulation of MCF-7/vector cells with E2
was associated with increases in Rab31 mRNA levels (Fig. 3B, left).
By contrast, E2 stimulation had no apparent effect on Rab31
expression in MCF-7/MUC1siRNA cells (Fig. 3B, right). Studies
performed with ZR-75-1/vector and ZR-75-1/MUC1siRNA cells
further demonstrated that MUC1-C is necessary for E2-induced
increases in Rab31 transcripts (Fig. 3C, left and right). Consistent
with these results, E2 stimulation of MCF-7 and ZR-75-1 cells was
associated with increases in Rab31 abundance (Fig. 3D, left and
right). Moreover, this response to E2 was attenuated by silencing
MUC1-C (Fig. 3E). These findings indicate that E2 stimulates
Rab31 expression at the mRNA and protein levels by a MUC1-C-
dependent mechanism.
MUC1-C Associates with ERa on the Rab31 Gene
Promoter
Coimmunoprecipitation studies performed on lysates from
MCF-7 cells demonstrated that MUC1-C associates with ERa
and that this interaction is increased in the response to E2
stimulation (Fig. 4A). Analysis of control and E2-stimulated ZR-
75-1 cells demonstrated similar results (Fig. 4B). Chromatin
immunoprecipitation (ChIP) studies were then performed on
control and E2-stimulated MCF-7 cells to assess the presence of
ERa and MUC1-C on the Rab31 promoter (Fig. 4C). Stimulation
with E2 was associated with a ,5-fold increase in ERa occupancy
compared to that obtained with a control IgG (Fig. 4D, left). Re-
ChIP studies further demonstrated that MUC1-C is detectable
with ERa on the Rab31 promoter (Fig. 4D, right). Analysis of ZR-
75-1 cells similarly showed that ERa occupancy of the Rab31
promoter is increased by E2 stimulation (Fig. 4E, left) and that this
response is associated with formation of ERa/MUC1-C complex-
es (Fig. 4E, right). These findings indicate that MUC1-C
coactivates Rab31 gene transcription by interacting with ERa on
the Rab31 promoter.
Rab31 Upregulates MUC1-C Expression
Rab31 functions in the trafficking of proteins, such as MUC1-C,
that are processed in early endosomes. To determine whether
Rab31 contributes to the regulation of MUC1-C, we silenced
Rab31 in MCF-7 cells. Notably, downregulation of Rab31 was
associated with a decrease in MUC1-C abundance (Fig. 5A, left).
Silencing of Rab31 in ZR-75-1 cells also resulted in a decline in
MUC1-C levels (Fig. 5A, right). Analysis of MUC1 transcripts by
qRT-PCR demonstrated that silencing Rab31 has no apparent
effect on MUC1-C expression at the mRNA level (data not
shown). Consequently, studies were performed to determine
whether Rab31 regulates processing of MUC1-C from the
endosome to the lysosome. Indeed, treatment of MCF-7/
Rab31siRNA cells with the lysosome inhibitor chloroquine (CQ)
was associated with an increase in MUC1-C abundance (Fig. 5B,
left). Similar results were obtained in CQ-treated ZR-75-1/
Rab31siRNA cells (Fig. 5B, right). To extend this analysis, we
examined Rab31 expression in non-malignant MCF-10A breast
epithelial cells. Compared to that in MCF-7 and ZR-75-1 cells,
Rab31 transcripts were substantially lower in MCF-10A cells
(Fig. 5C). Moreover, Rab31 and MUC1-C protein levels were in
lower abundance in MCF-10A cells relative to that in the breast
cancer cells (Fig. 5D). We therefore transfected MCF-10A cells to
stably express Rab31 or an inactive Rab31(S20N) mutant (Fig. 5E).
Expression of Rab31 in MCF-10A cells was associated with a
modest increase in MUC1-C levels (Fig. 5E). In contrast, the
Rab31(S20N) mutant completely suppressed MUC1-C expression
(Fig. 5E). As a control, levels of EGFR protein were unaffected by
expression of Rab31 or Rab31(S20N) (Fig. 5E), supporting the
selective effects of Rab31 on MUC1-C expression.
MUC1-C and Rab31 Function in an Autoinductive Loop
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Mammospheres by a MUC1-C-dependent Mechanism
To assess affects of Rab31 on growth, the MCF-10A cells were
first seeded in soft agar. MCF-10A/vector cells failed to form
colonies (Fig. 6A, left). In contrast, MCF-10A/Rab31 cells formed
colonies and this response was substantially suppressed with the
Rab31(S20N) mutant (Fig. 6A, left and right). Mammosphere
structures are formed by culturing tumor-initiating cells under
nonadherent and nondifferentiating conditions [18,19]. In concert
with previous observations with parental MCF-10A cells [20],
MCF-10A/vector cells failed to form mammospheres (Fig. 6B,
left). However, mammospheres were formed with MCF-10A/
Rab31 cells (Fig. 6B, left). Moreover, for MCF-10A/Rab31(S20N)
cells, small clusters were detectable that did not develop into
mammosphere structures (Fig. 6B, left). Quantitation of mammo-
sphere number confirmed dependence of MCF-10A cells on
Rab31 for development of these structures (Fig. 6B, right).
Immunoblot of MCF-10A/Rab31 cells growing as a monolayer
and as mammospheres demonstrated the marked upregulation of
MUC1-C levels under the mammosphere culture conditions
(Fig. 6C, left). To assess involvement of MUC1-C in mammo-
sphere formation, MUC1-C was silenced in the MCF-10A/Rab31
cells (Fig. 6C, right). Analysis of the MCF-10A/Rab31 cells
expressing a control or MUC1 siRNA demonstrated that silencing
MUC1-C is associated with a significant decrease in the formation
of mammospheres (Fig. 6E, left and right). Using another
approach to assess involvement of MUC1-C, we treated the
MCF-10A/Rab31 cells with the cell-penetrating peptide GO-203
that blocks MUC1-C function [21,22]. As a control, cells were also
treated with an inactive cell-penetrating peptide CP-2. Treatment
Figure 1. MUC1 induces Rab31 expression. A and B. RNA from the indicated MCF-7 (A) and ZR-75-1 (B) cells was analyzed by RT-PCR using
primers designed to detect the indicated transcripts (left). RNA was also analyzed for Rab31 mRNA levels by qRT-PCR (right). The results (mean6SD of
three determinations) are expressed as relative Rab31 mRNA levels compared to that obtained in the vector cells. C and D. Lysates from the indicated
MCF-7 (C) and ZR-75-1 (D) cells were immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0039432.g001
Figure 2. Activation of the Rab31 promoter by MUC1 and ERa. A. Schematic representation of the Rab31 promoter with localization of
putative estrogen response elements (EREs). B and C. The indicated MCF-7 (B) and ZR-75-1 (C) cells were transfected with pRab31-Luc and Renilla
plasmids for 48 h and then assayed for luciferase activity. The results are expressed as the relative luciferase activity (mean6SD of three
determinations) compared to that obtained in the vector cells. D. MCF-7 cells were transiently transfected with control and ERa siRNA pools. Lysates
were immunoblotted with the indicated antibodies (left). The cells were also transfected with pRab31-Luc and Renilla plasmids for 48 h. The results
are expressed as the relative luciferase activity (mean6SD of three determinations) compared to that obtained in the CsiRNA-transfected cells (right).
E. ZR-75-1 cells were transfected with pRab31-Luc and Renilla plasmids for 24 h. The cells were then cultured in phenol red-free medium with 2%
charcoal dextran-treated serum for 72 h, treated with E2 for 24 h and assayed for luciferase activity. The results are expressed as the relative luciferase
activity (mean6SD of three determinations) compared to that obtained in the untreated control (CTL) cells.
doi:10.1371/journal.pone.0039432.g002
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decrease in mammosphere formation (Figs. 6F, left and right).
These findings indicate that Rab31 confers the ability of MCF-
10A cells to form mammospheres by a MUC1-C-dependent
mechanism.
Expression of Rab31 and MUC1 in Human Breast Cancers
Analysis of Rab31 expression in the GSE5764 dataset from 20
normal breast tissues and 10 breast tumors demonstrated that
Rab31 mRNA levels are significantly higher in breast cancers as
compared to normal breast tissue (Fig. 7A). Analysis of the
GSE5460 dataset of 76 ER+ and 53 ER2 breast tumors further
demonstrated that MUC1 expression is significantly higher in
ER+ as compared to ER- cancers (Fig. 7B, left). Rab31 expression
levels were also significantly higher in ER+ breast cancers (Fig. 7B,
right). In the dataset of Loi et al. [23], there are 262 patients with
ER+ and 45 patients with ER- breast cancers. MUC1 was
expressed in 46.6% (122) of ER+ tumors and 11.1% (5) of ER-
tumors (Fisher’s exact test, p,0.0001) (Fig. 7C, left). Rab31 was
expressed in 46.2% (121) of ER+ tumors and 24.4% (11) of ER-
tumors (Fisher’s exact test, p=0.0086) (Fig. 7C, middle). Notably,
MUC1 and Rab31 were more likely to be co-expressed in ER+
tumors (n=59, 22.5%) than ER- tumors (n=3, 6.67%) (Fisher’s
exact test, p=0.015) (Fig. 7C, right). This analysis was expanded
to the dataset of van de Vijver et al. [24], in which there are 226
patients with ER+ and 69 patients with ER- breast cancers.
MUC1 was expressed in 46.0% (104) of ER+ tumors and 17.4% of
ER- tumors (12) (Fisher’s exact test, p,0.0001) (Fig. 7D, left).
Rab31 was expressed in 42.9% (97) of ER+ tumors and 13.0% (9)
of ER- tumors (Fisher’s exact test, p,0.0001) (Fig. 7D, middle).
These results also confirm that MUC1 and Rab31 were more
likely to be co-expressed in ER+ tumors (n=51, 22.6%) than ER-
tumors (n=3, 4.35%) (Fisher’s exact test, p=0.0003) (Fig. 7D,
left). We therefore focused on analysis of the dataset of Chanrion
et al. composed of 147 patients with ER+ breast tumors [25].
MUC1 was expressed in tumors from 25 patients (17.0%), while
Rab31 was expressed in tumors from 30 patients (20.4%) (Fig. 7E,
left). The association between MUC1 and Rab31 expression was
highly significant (Fisher’s exact test, p,0.0001) in that MUC1-
positive tumors were more likely than MUC1-negative tumors to
express Rab31 (n=22, 88.0% vs. n=8, 6.56%). Moreover,
patients with Rab31-positive tumors had a significantly decreased
ten-year overall survival compared with patients with Rab31-
negative tumors (35.3% versus 65.9%) (log-rank test, p,0.0001)
(Fig. 7E, right).
Discussion
MUC1-C Upregulates Rab31 Expression
The overexpression of MUC1 in human breast cancers is
associated with targeting of the MUC1-C subunit to the nucleus
where it interacts with ERa [7,9,17]. The present studies
demonstrate that silencing of MUC1-C in ER+ breast cancer
cells is associated with downregulation of transcripts encoding the
Rab31 GTPase. Little is known about the function of Rab31,
other than it is involved in the trafficking of proteins in endosomes
[3,4,5]. In addition, high levels of Rab31 in tumors from patients
with node-negative breast cancers have been associated with
decreased survival [6]. However, to our knowledge, there has been
no known association between Rab31 and effectors linked to
breast cancer. The present findings support a model in which the
MUC1-C oncoprotein activates Rab31 expression by an ERa-
mediated mechanism. MUC1-C stabilizes ERa by blocking its
ubiquitination and degradation [17]. MUC1-C also associates
with ERa on estrogen-responsive promoters, enhances ERa
occupancy, increases recruitment of p160 coactivators and
antagonizes the inhibitory effects of tamoxifen [17]. In the present
studies, analysis of the Rab31 promoter identified potential ERa
Figure 3. E2-induced Rab31 expression is dependent on MUC1. A. RNA from MCF-7 (left) and ZR-75-1 (right) cells stimulated with E2 for the
indicated times was analyzed by qRT-PCR. The results (mean6SD of three determinations) are expressed as relative Rab31 mRNA levels compared to
that obtained in unstimulated cells. B and C. RNA from the indicated MCF-7 (B) and ZR-75-1 (C) cells stimulated with E2 for 0, 6 or 24 h was analyzed
by qRT-PCR. The results (mean6SD of three determinations) are expressed as relative Rab31 mRNA levels compared to that obtained in the
unstimulated vector cells. D. Lysates from MCF-7 (left) and ZR-75-1 (right) cells stimulated with E2 for 0, 6 and 24 h were immunoblotted with the
indicated antibodies. E. Lysates from the indicated MCF-7 cells stimulated with E2 for 0, 6 and 24 h were immunoblotted with the indicated
antibodies.
doi:10.1371/journal.pone.0039432.g003
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ERa suppressed activation of a Rab31 promoter-reporter and
decreased Rab31 mRNA levels, indicating that Rab31 gene
transcription is driven by ERa signaling. To our knowledge,
Rab31 expression had not been previously linked to ERa-
mediated transactivation and this finding provided the basis for
assessing the potential involvement of MUC1-C. Indeed, in
support of the regulation of Rab31 by MUC1-C, complexes of
ERa and MUC1-C were detectable on the Rab31 promoter.
Moreover, silencing MUC1-C suppressed (i) Rab31 promoter
activation, (ii) Rab31 mRNA levels, and (iii) E2-induced Rab31
expression. There had previously been no available information
on how the Rab31 gene is regulated in breast cancer cells,
particularly those that express high Rab31 levels. Our results
support a model in which the Rab31 gene is activated by both
MUC1-C and ERa in breast cancer cells. These findings,
however, do not exclude the possibility that MUC1-C could also
contribute to Rab31 expression by ERa-independent mechanisms.
Rab31 Cooperates with MUC1-C in a Potential
Autoinductive Loop
Expression of the MUC1-C subunit at the cell membrane is
regulated by clathrin-mediated endocytosis [14,15]. The role of
Rab31 in the trafficking of certain proteins in endosomes invoked
the possibility that MUC1-C-mediated induction of Rab31
expression could, in turn, affect MUC1-C levels. Indeed, silencing
of Rab31 in breast cancer cells was associated with a decrease in
MUC1-C protein, but not transcripts, indicating that Rab31
might prevent processing of endosomal MUC1-C for degradation
in lysosomes. In concert with such a model, chloroquine treatment
of breast cancer cells silenced for Rab31 was associated with
increases in MUC1-C abundance, indicating that Rab31 promotes
recycling of MUC1-C, as opposed to its lysosomal degradation.
The interaction between Rab31 and MUC1-C was further
supported by studies in non-malignant MCF-10A breast epithelial
cells, which express low levels of Rab31. Introduction of Rab31 in
MCF-10A cells was associated with a modest increase in MUC1-C
levels. Strikingly, expression of an inactive Rab31(S20N) mutant
resulted in complete suppression of MUC1-C abundance, a
response that was selective for MUC1-C in that Rab31(S20N) had
no effect on EGFR levels. Rab31, but not Rab31(S20N), also
conferred the ability of MCF-10A cells to form mammospheres.
Under these nonadherent and nondifferentiating conditions of
culturing the MCF-10A/Rab31 cells, the formation of mammo-
spheres was decreased by silencing MUC1-C expression. In
addition, treatment of the MCF-10A/Rab31 cells with GO-203,
an inhibitor of MUC1-C function, blocked mammosphere
formation. These results thus provide support for a cooperative
interaction between MUC1-C and Rab31. MUC1-C activates
Figure 4. MUC1-C associates with ERa on the Rab31 promoter. A and B. Lysates from MCF-7 (A) and ZR-75-1 (B) cells left untreated or
stimulated with E2 for 24 h were immunoprecipitated with anti-ERa or a control IgG. The precipitates were immunoblotted with anti-MUC1-C or anti-
ERa. C. Schema of the Rab31 promoter highlighting the positions of the control region (CR) and the proximal region encompassing estrogen
response elements (EREs). D and E. Soluble chromatin from MCF-7 (D) and ZR-75-1 (E) cells left untreated or stimulated with E2 for 24 h was
precipitated with a control IgG or anti-ERa. The precipitates were analyzed for Rab31 promoter ERE or CR sequences (left). The results (mean6SD of
three determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control. In re-ChIP experiments, the anti-
ERa precipitates were released, reimmunoprecipitated with anti-MUC1-C, and then analyzed for Rab31 promoter sequences (right). The results
(mean6SD of three determinations) are expressed as the relative fold enrichment compared to that obtained with the unstimulated control.
doi:10.1371/journal.pone.0039432.g004
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in a positive feedback autoinductive loop. In this capacity, the
functional significance of such a loop is that Rab31 alters the
growth characteristics of breast epithelial cells, at least in part, by a
MUC1-C-dependent mechanism.
Association of MUC1 and Rab31 Expression in ER+ Breast
Cancers
An experimental model of MUC1-C-induced transformation
identified the activation of gene families involved in oncogenesis
[26]. Application of MUC1-C-induced genes associated with
tumorigenesis to breast cancer databases predicted significant
decreasesindisease-freeandoverallsurvival[26].Rab31expression
in breast cancers is also significantly associated with decreases in
overall survival [6]. The present results demonstrate that Rab31
expression is significantly higher in breast tumors as compared to
normalbreasttissue.Inadditionandinconcertwithourfindingthat
ERa activates Rab31 gene transcription, Rab31 expression was also
significantly higher in ER+ as compared to ER- breast cancers. As
noted above, Rab31 expression is not restricted to ER+ breast
cancer cells,indicating that ERa-independent mechanisms canalso
contribute to Rab31 gene transcription. Our results further
demonstrate that Rab31 and MUC1 are significantly co-expressed
in ER+ breast cancers. These findings are thus consistent with a
model in which MUC1-C coactivates ERa-mediated Rab31
transcription in breast cancer cells growing in vitro and as primary
tumors. Other studies have demonstrated that MUC1-C induces
genes involved in cholesterol and fatty acid metabolism [27]. The
MUC1-C-induced gene set associated with lipid metabolism was
appliedtotwoindependentdatabasesfrompatientswithER+breast
tumors who were treated with tamoxifen. The results showed that
patients with tumors expressing MUC1 and the lipid metabolic
pathwaysareathigherriskforrecurrenceanddeath[27].Apositive
correlation was also found between the MUC1-C-induced gene set
and the ER signaling pathway [27]. These findings indicate that the
autoinductive loop between MUC1-C and Rab31 found in ER+
Figure 5. Rab31 upregulates MUC1-C expression. A. MCF-7 (left) and ZR-75-1 (right) cells were stably transfected to express a control siRNA
(CsiRNA) or a Rab31 siRNA. Lysates from the transfectants were immunoblotted with the indicated antibodies. B. MCF-7/Rab31siRNA (left) and ZR-75-
1/Rab31siRNA (right) cells were treated with the indicated concentrations of chloroquine (CQ) for 24 h. Lysates from the treated cells were
immunoblotted with the indicated antibodies. C. RNA from MCF-7, ZR-75-1 and MCF-10A cells was analyzed for Rab31 mRNA levels by qRT-PCR. The
results (mean+SD of three determinations) are expressed as relative Rab31 mRNA levels compared to that obtained for MCF-7 cells. D. Lysates from
MCF-7, ZR-75-1 and MCF-10A cells were immunoblotted with the indicated antibodies. E. MCF-10A cells were stably transfected to express an empty
vector, Rab31 or Rab31(S20N). Lysates from the transfected cells were immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0039432.g005
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part, to ER+ breast tumors that fail to respond to tamoxifen
treatment.AdirectinhibitorofMUC1-Cispresentlyunderstudyin
a PhaseItrial forpatients withrefractorysolid tumors.Based on the
presentfindings,patientswithbreastcancerthatco-expressMUC1-
C and Rab31, and perhaps are resistant to tamoxifen, could be
candidates for the targeting of MUC1-C with this agent.
Materials and Methods
Cell Culture
Human MCF-7 breast cancer cells were cultured in Dulbecco’s
modified Eagle’s medium with 10% heat-inactivated fetal bovine
serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin and
2 mM L-glutamine. Human ZR-75-1 cells were grown in RPMI-
1640 medium (ATCC) with 10% FBS, antibiotics and L-
glutamine. Human MCF-10A mammary epithelial cells were
grown in mammary epithelial growth medium (MEGM, Lonza).
In certain experiments, cells were cultured in phenol red-free
MEM medium containing 2% charcoal dextran-treated calf serum
and then treated with 10 nM estradiol (E2; Sigma). Cells were also
treated with chloroquine (CQ; Sigma). Stable silencing of MUC1
or Rab31 was performed by transduction of cells with a lentivirus
expressing Mission shRNAs (Sigma) and selection in puromycin.
For ERa silencing, cells were transfected with smart pool ERa
siRNAs (Dharmacon).
RT-PCR and qRT-PCR
Total RNA was isolated from cells using an RNeasy Mini kit
(Qiagen). cDNAs were synthesized with 0.3–1 mg RNA using the
first-strand cDNA synthesis kit (Invitrogen). Expression of Rab31,
MUC1 and b-actin was analyzed with 1 ml of cDNA using Taq
DNA polymerase (Promega). For quantitative PCR, the SYBR
green qPCR assay kit (Applied Biosystems) was used with 5 mlo f
20-fold diluted cDNA from each sample, and the samples were
amplified with the ABI Prism 7300 machine (Applied Biosystems).
Primers used for RT-PCR and qRT-PCR are listed in Tables S1
and S2, respectively.
Immunoprecipitation and Immunoblot Analysis
Cell lysates were incubated with control IgG or anti-ERa (Santa
Cruz Biotechnology) overnight at 4uC. Protein G-Sepharose beads
(GE Health Care Life Sciences) were added for another 2 h. The
immunoprecipitates and lysates not subjected to precipitation were
immunoblotted with anti-Rab31 (C-15; Santa Cruz Biotechnolo-
Figure 6. Rab31 promotes MCF-10A mammosphere formation by a MUC1-C-dependent mechanism. A. The indicated MCF-10A cells
were seeded in soft agar. After culturing for 3 weeks, photomicrographs were obtained (left) and the numbers of colonies (mean6SD of three
replicates) were determined by counting clusters of .20 cells. B. The indicated MCF-10A cells were seeded under conditions for the growth of
mammospheres. After culturing for 3 weeks, photomicrographs were obtained (left) and the numbers of mammospheres (mean6SD of three
replicates) were determined by counting spheres of .20 cells (right). C. Lysates from MCF-10A/Rab31 cells grown as an adherent monolayer and as
mammospheres were immunoblotted with the indicated antibodies (left). MCF-10A/Rab31 cells were transfected with control and MUC1 siRNAs.
Lysates were immunoblotted with the indicated antibodies (right). D. MCF-10A/Rab31 cells transfected with the indicated siRNAs were cultured for
the growth of mammospheres. After 3 weeks, photomicrographs were obtained (left) and the numbers of mammospheres (mean6SD of three
replicates) were determined by counting spheres of .20 cells (right). E. MCF-10A/Rab31 cells were cultured for the growth of mammospheres in the
absence (Control) and presence of 5 mM GO-203 or CP-2. After 3 weeks, photomicrographs were obtained (left) and the numbers of mammospheres
(mean6SD of three replicates) were determined by counting spheres of .20 cells (right).
doi:10.1371/journal.pone.0039432.g006
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PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e39432gy), anti-MUC1-C (Ab5; Neomarkers), anti-ERa, anti-EGFR
(Santa Cruz Biotechnology) and anti-b-actin (Sigma). Immune
complexes were detected with horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence (Amer-
sham Biosciences).
Figure 7. Expression of Rab31 in human breast cancers. A. Analysis of Rab31 mRNA levels in the GSE5764 dataset from 23 normal breast
tissues and 10 breast tumors. The results are expressed as the relative Rab31 mRNA levels based on the normalization values in the dataset. B.
Analysis of MUC1 mRNA (left) and Rab31 mRNA (right) levels in the GSE5460 dataset from 76 ER+ and 53 ER2 breast tumors. Normalized microarray
data were separated into ER+ and ER- groups. C and D. Analysis of MUC1 mRNA (left), Rab31 mRNA (middle) and co-expression levels (right) in the Loi
dataset (C, 262 ER+ and 45 ER2 breast tumors) and van de Vijver dataset (D, 226 ER+ and 69 ER2 breast tumors). E. Analysis of Rab31 and MUC1
mRNA co-expression levels in 147 ER+ breast tumors (left). Percentage overall survival for patients with Rab31-positive versus Rab31-negative breast
tumors (right; Chanrion dataset).
doi:10.1371/journal.pone.0039432.g007
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The Rab31 promoter region from 21t o21874 was cloned into
the pGL3 luciferase vector (Promega). Control pGL3 or pRab31-
Luc constructs were transfected with the Renilla plasmid into cells
in the presence of Lipofectamine. At 48 h after transfection, cells
were lysed, and luciferase reporter activity was measured using the
Promega Dual Glo kit.
Chromatin Immunoprecipitation (ChIP) Assays
Soluble chromatin was prepared from 2–3610
6 cells as
described [28] and precipitated with anti-ERa or a control
nonimmune IgG. For re-ChIP assays, complexes from the initial
ChIP were eluted and reimmunoprecipitated with anti-MUC1-C
as described [28]. For PCR, 2 ml from a 50 ml DNA sample was
used with the indicated primers (Table S3) and 25–35 cycles of
amplification. Fold enrichment was calculated as described [28].
Site-directed Mutagenesis
The Rab31(S20N) mutant was generated using the Quikchange
XLII Site-Directed Mutagenesis kit (Stratagene).
Colony Formation in Soft Agar
Cells (3610
4) were suspended in 2 ml of 0.35% (wt/vol) agar
containing DMEM/10% fetal bovine serum and overlaid onto a
0.75% (wt/vol) agar solution in 6-well plates. One ml of fresh
medium was added once a week. Colonies .20 cells were counted
and imaged after 3 weeks of incubation.
Mammosphere Formation
Cells (4610
4) in 2 ml serum-free DMEM/F12 (Invitrogen)
media, supplemented with B27 (1:50, Invitrogen), 0.4% BSA,
20 ng/ml EGF, and 4 mg/ml insulin (Sigma) were seeded in 6-well
ultra-low adherent plates (StemCell Technologies). At 3 weeks,
spheres containing .20 cells were photographed and counted.
Analysis of Breast Cancer Datasets
Five publicly available datasets were analyzed that contain
normal or breast tumor expressional data from 30 [29], 129 [30],
307 [23], 295 [24], and 147 [25] patients. All statistical analyses
were performed using JMP 9.0 (SAS Institute Inc., Cary, NC,
USA). The raw signal intensity for each probe set ID of interest for
each patient was normalized to the average value of the probe set
ID across all patients. Multiple probe set IDs for a given gene were
averaged for each patient sample to obtain a representative
expression value for each gene. MUC1 and Rab31 expression
were defined as having a normalized expression value greater than
one. Fisher’s exact test was used to determine differences in
association between two groups. Survival analysis was performed
using Kaplan-Meier statistics with log-rank tests to test the null
hypothesis of no difference in survival functions between patient
groups.
Supporting Information
Table S1 Primers used for RT-PCR of Rab31 and
MUC1.
(RTF)
Table S2 Primers used for qRT-PCR of Rab31.
(RTF)
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